Destiny Pharma’s Update on Phase 2b clinical study of lead asset XF-73 in the prevention of post-surgical bacterial infections

Protocol amendment agreed with FDA to reduce Phase 2b study size without compromising its statistical power or clinical value Study two thirds enrolled. Recruitment now expected to complete year end Planned study interim safety review to be announced in August 2020 Brighton, United Kingdom – 27 July 2020 – Destiny Pharma plc (AIM: DEST), […]

CalciMedica and EpiPharma Enter into Research Collaboration to Discover and Develop CRAC Channel Inhibitor Therapies

Under the terms of the research collaboration agreement, CalciMedica will use EpiPharma’s state of the art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate its drug discovery pipeline La Jolla, Calif., USA; Szeged and Budapest, Hungary July 15, 2020 – CalciMedica, a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of […]

CalciMedica Announces Data Showing Auxora™ Substantially Improved Outcomes in Patients with Severe COVID-19 Pneumonia

Link to Full Article Median time to recovery was more than two times faster for patients treated with Auxora plus standard of care compared to standard of care alone The percentage of patients requiring invasive mechanical ventilation was 2.8 times lower with Auxora plus standard of care compared to standard of care alone Treating 2.6 […]

Congenica Automation Further Accelerates Identification of Genetic Diseases

Link to Full Article   Cambridge, United Kingdom – 15 July 2020 – Congenica has launched Congenica Automation, an update for its clinical decision support platform that will provide automated classification, evidence and reporting of recurrent ‘known’ variants that customers observe in their rare disease cases, significantly saving time while maximizing diagnostic yield and laboratory throughput. The key […]

Pharma companies join forces to launch $1 billion fund to develop new antibiotics 2030

Link to Full Article Twenty-three leading biopharmaceutical companies have joined forces to invest $1 billion in a fund to develop new antibiotics, which are needed urgently to fight the worldwide rise in antimicrobial-resistant superbugs. The AMR Action Fund, aims to bring 2-4 new antibiotics to patients 2030. Through the AMR Action Fund, pharmaceutical companies will join […]